Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials

Diabetes and Metabolism

Volumn 44, Issue 5, 2018, Pages 410-414

  Li, D ^a   Yang, J Yufeng ^b   Wang, T ^b   Shen, S ^a   Tang, H ^c,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b The University of North Carolina at Chapel Hill   (United States)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Amputation; Diabetic foot syndrome; Meta analysis; SGLT2i; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

ARTICLE; DIABETES MELLITUS; DIABETIC FOOT; DISEASE ASSOCIATION; DRUG SAFETY; FOOT AMPUTATION; HUMAN; INSULIN TREATMENT; META ANALYSIS; AMPUTATION; CHEMICALLY INDUCED; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

AMPUTATION; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85042605533     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2018.02.001     Document Type: Article

References (33)

1. Singh, N., Armstrong, D.G., Lipsky, B.A., Preventing foot ulcers in patients with diabetes. JAMA 293 (2005), 217–228.
2. Pecoraro, R.E., Reiber, G.E., Burgess, E.M., Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 13 (1990), 513–521.
3. Ward, A., Alvarez, P., Vo, L., Martin, S., Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 17 (2014), 176–183.
4. Hasan, R., Firwana, B., Elraiyah, T., Domecq, J.P., Prutsky, G., Nabhan, M., et al. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J Vasc Surg 63 (2016), 22S–28S.
5. Ferrannini, E., Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8 (2012), 495–502.
6. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in Type 2 Diabetes. N Engl J Med 377 (2017), 644–657.
7. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). US Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm. Accessed May 16, 2017.
8. Udell, J.A., Yuan, Z., Rush, T., Sicignano, N.M., Galitz, M., Rosenthal, N., Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL Population-Based Cohort Study. Circulation, 2017 [ahead of print].
9. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
10. Higgins, J.P.T., Altman, D.G., Sterne, A.C., Chapter 8: assessing risk of bias in included studies. Higgins J., Green S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 510, 2011, The Cochrane Collaboration [Updated March 2011. http://handbook.cochrane.org/.chapter_8/8_assessing_risk_of_bias_in_included_studies.htm. Accessed June 28, 2016].
11. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
12. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med 373 (2015), 2117–2128.
13. Lewin, A., DeFronzo, R.A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38 (2015), 394–402.
14. DeFronzo, R.A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38 (2015), 384–393.
15. Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H.J., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
16. Haring, H.U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U.C., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
17. Kovacs, C.S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H.J., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2014), 147–158.
18. Leymarie, F., Richard, J.L., Malgrange, D., Factors associated with diabetic patients at high risk for foot ulceration. Diabetes Metab 31 (2005), 603–605.
19. Selby, J.V., Zhang, D., Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 18 (1995), 509–516.
20. Feng, Y., Schlosser, F.J., Sumpio, B.E., The Semmes Weinstein monofilament examination is a significant predictor of the risk of foot ulceration and amputation in patients with diabetes mellitus. J Vasc Surg 53 (2011), 220–226.
21. Fadini, G.P., Avogaro, A., SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5 (2017), 680–681.
22. Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
23. Hawley, S.A., Ford, R.J., Smith, B.K., Gowans, G.J., Mancini, S.J., Pitt, R.D., et al. The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels. Diabetes 65 (2016), 2784–2794.
24. EMA Pharmacovigilance Risk Assessment Committee recommendation: PRAC concludes that diabetes medicine canagliflozin may contribute to risk of toe amputation. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500221431.pdf. Accessed February 10, 2017.
25. Monami, M., Zannoni, S., Nreu, B., Mannucci, E., Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol 54 (2017), 411–413.
26. Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
27. Cefalu, W.T., Leiter, L.A., de Bruin, T.W., Gause-Nilsson, I., Sugg, J., Parikh, S.J., Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with Type 2 diabetes: a 24-week, multicenter, randomized, double-blind, Placebo-Controlled Study with a 28-week extension. Diabetes Care 38 (2015), 1218–1227.
28. Leiter, L.A., Yoon, K.H., Arias, P., Langslet, G., Xie, J., Balis, D.A., et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 38 (2015), 355–364.
29. Ridderstrale, M., Andersen, K.R., Zeller, C., Kim, G., Woerle, H.J., Broedl, U.C., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
30. Roden, M., Merker, L., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol, 14, 2015, 154.
31. Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
32. Yale, J.F., Bakris, G., Cariou, B., Nieto, J., David-Neto, E., Yue, D., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16 (2014), 1016–1027.
33. Kohler, S., Zeller, C., Iliev, H., Kaspers, S., Safety and tolerability of empagliflozin in patients with Type 2 Diabetes: pooled analysis of Phase I-III Clinical Trials. Adv Ther 34 (2017), 1707–1726.